JAK抑制剂治疗急性重度溃疡性结肠炎:乌帕替尼与托法替布及挽救与序贯挽救治疗比较
多中心回顾性队列研究纳入150例急性重度溃疡性结肠炎患者,比较乌帕替尼与托法替布及挽救与序贯挽救治疗。52周结肠切除率33%,乌帕替尼显著低于托法替布(23.4% vs 42.5%,p=0.022),序贯挽救治疗结肠切除率数值更高但无统计学差异。
要点
- 乌帕替尼较托法替布显著降低52周结肠切除率(23.4% vs 42.5%,p=0.022)。
- 序贯挽救治疗结肠切除率38% vs 挽救治疗30%,差异无统计学意义(p=0.239)。
- JAK抑制剂用于急性重度溃疡性结肠炎安全有效,随访中乌帕替尼临床缓解率更高。
核心结论
- JAK抑制剂治疗急性重度溃疡性结肠炎有效且安全性良好。
- 乌帕替尼较托法替布显著降低52周结肠切除率,并提高随访期间临床缓解、无激素临床缓解和生化缓解率。
- 序贯挽救治疗可能为面临结肠切除的患者提供可行选择。
研究设计与样本
- 多中心回顾性队列研究,覆盖澳大利亚13个炎症性肠病中心。
- 纳入2021年4月至2024年4月启动乌帕替尼或托法替布的成人急性重度溃疡性结肠炎患者,共150例,随访至52周。
主要发现
- 乌帕替尼使用率51%,托法替布49%;作为挽救治疗69%,序贯挽救治疗31%。
- 52周结肠切除率33%,乌帕替尼组23.4%显著低于托法替布组42.5%(加权边际风险差-0.18,p=0.022),早期时间点无显著差异。
- 序贯挽救治疗结肠切除率38% vs 挽救治疗30%(校正边际风险差-0.1,p=0.239),无统计学意义。
临床怎么用
- 对于急性重度溃疡性结肠炎,可考虑使用JAK抑制剂作为挽救治疗。
- 乌帕替尼可能较托法替布更有利于降低52周结肠切除风险。
- 序贯挽救治疗可作为面临结肠切除患者的可选策略。
局限性
- 回顾性队列设计可能存在选择偏倚和混杂因素。
- 样本量150例,序贯挽救治疗比较的统计学效能可能不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute Severe Ulcerative Colitis (ASUC) remains a medical emergency with limited therapeutic options. Upadacitinib and tofacitinib are Janus kinase (JAK) inhibitors being increasingly used as rescue therapy for ASUC with limited data. We evaluated outcomes of JAK inhibitor use for ASUC over 52 weeks. METHODS: We undertook a multicentre retrospective cohort study across 13 Australian IBD centres. Adults with ASUC who commenced upadacitinib or tofacitinib from April 2021 to April 2024 were included. Outcomes were assessed during index admission, at week 8, 16, and 52. Comparisons of upadacitinib vs tofacitinib and rescue vs sequential salvage therapy were undertaken. The primary outcome for both analyses was colectomy by week 52. RESULTS: 150 patients were included with complete follow-up to 52 weeks. Upadacitinib was used in 51%, tofacitinib in 49%; JAK inhibitors as rescue therapy in 69% and sequential salvage therapy in 31%. Colectomy occurred in 33% of patients by week 52, and was significantly lower with upadacitinib than tofacitinib (23.4% vs 42.5%, weighted marginal risk difference -0.18, p=0.022), with no significance at earlier timepoints. Sequential salvage therapy resulted in a numerically higher rate of colectomy compared to Rescue therapy (38% vs 30%, adjusted marginal risk difference -0.1, p=0.239), but did not meet statistical significance. CONCLUSION: JAK inhibitors were effective for ASUC with a reassuring safety profile. Upadacitinib use resulted in a significantly lower rate of colectomy by week 52, with higher rates of clinical remission, CFCR, and biochemical remission during follow-up. Sequential salvage therapy may represent a viable therapeutic option for patients otherwise facing colectomy.
引用
- R G, R F, N G, et al. Janus Kinase Inhibitors for Acute Severe Ulcerative Colitis: Comparing Upadacitinib to Tofacitinib and Rescue to Sequential Salvage therapy. Clin Gastroenterol Hepatol. 2026. PMID: 42772622. doi:10.1016/j.cgh.2026.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。